{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009478","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.451104+00:00","generated_at":"2026-06-17T18:55:54.093846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Erasca reports Q4/FY2022 net loss of $135.3M/$242.8M; licensed naporafenib from Novartis, raised $100M equity","bullets":["Net loss Q4 2022 $135.3M (incl. $100M in-process R&D for naporafenib license); FY2022 net loss $242.8M ($1.99/share).","Cash, cash equivalents & marketable securities $435.6M at Dec 31, 2022; expected runway into H2 2025.","Completed $100M underwritten equity offering (15.4M shares at $6.50) in Dec 2022 concurrent with naporafenib license.","Multiple data readouts planned in 2023 for ERAS-007, ERAS-601, ERAS-801; naporafenib Phase 1b (SEACRAFT-1) starts H2 2023.","R&D expenses FY2022 $112.5M (up 52% YoY) driven by license payments and clinical progress."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009478","json":"https://secwatch.observer/filing/0000950170-23-009478.json","markdown":"https://secwatch.observer/filing/0000950170-23-009478.md","text":"https://secwatch.observer/filing/0000950170-23-009478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/eras-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:55:54.093846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18f3698032d517f6d58c70a61d83fea08165f580","claim":"Erasca, Inc. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6d5601f6ac916deecf1008c558f1e0acf5903fc6","claim":"Erasca, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}